Regulation & Approvals
Wanbury's Tanuku API Facility Clears South Korea MFDS cGMP Inspection With Zero Observations
By News Desk ·
Key takeaways
- Wanbury's Tanuku API facility passed a South Korea MFDS cGMP inspection with zero observations after a three-day review by two senior inspectors.
- The Tanuku result follows a zero-observation MFDS cGMP inspection at Wanbury's Patalganga facility in April 2026.
- Wanbury's Tanuku site received an Australian TGA GMP compliance certificate issued October 28, 2026, covering six APIs and valid until December 9, 2028.
Wanbury's Tanuku active pharmaceutical ingredient facility has passed a Current Good Manufacturing Practice inspection by South Korea's Ministry of Food and Drug Safety with zero observations, ScanX reported on November 20, 2026. Wanbury is an Indian pharmaceutical company that makes APIs and formulations and exports to more than 50 countries, according to its own site.
Inside the Tanuku MFDS Inspection
Two senior inspectors from the South Korean regulator conducted the review over three days, covering the Tanuku facility's compliance with applicable Good Manufacturing Practice standards. The MFDS is South Korea's primary regulator for the safety and quality of pharmaceutical products and their manufacturing processes, and a clean cGMP outcome is a prerequisite for supplying API products to the South Korean market.
The result follows a similar MFDS cGMP inspection at Wanbury's Patalganga manufacturing facility in April 2026, which also concluded with zero observations. Wanbury said the consecutive achievements reflect its commitment to quality, regulatory compliance and operational excellence, and that it remains focused on strengthening its quality systems and manufacturing standards in line with international regulatory requirements and global cGMP expectations.
Earlier Clearances at Tanuku and Patalganga
Wanbury received a TGA GMP compliance certificate for its Tanuku facility after an inspection on June 8-9, 2026, Machine Maker reported. The certificate, issued October 28, 2026, covers six APIs and remains valid until December 9, 2028. In August 2026, Wanbury received EDQM approval for its Rivaroxaban API, enabling it to meet customer demand in the EU, Business Standard reported.
How Peers Fared on GMP Reviews
USV Private Limited received a warning letter from the FDA over three violations at its India facility, including a lack of procedures for microbial and particulate contamination, FiercePharma reported on November 17, 2026. Smruthi Organics received a Brazilian GMP certificate from ANVISA for Levanlodipine Besylate Hemipentahydrate at its Unit II facility in Solapur, ScanX reported on November 12, 2026; the certificate was issued October 26, 2026 and is valid until October 26, 2028. Boryung's Yesan Campus secured EU-GMP certification for solid formulations after a German inspection, Businesskorea reported on November 10, 2026.
What Comes Next for Wanbury
Wanbury plans to resume dispatches of Ketamine HCl API following regulatory audits, with first shipments planned for November 2026, the company said. Wanbury Skin Health Limited, an 82% subsidiary, launched its berrysoft baby product range in October 2026.
Companies in this story
- Wanbury · www.wanbury.com